Moteur de recherche d’entreprises européennes
Financement de l’UE (3 493 219 €) : Outils d’évaluation des risques en cas d’effets secondaires graves après une thérapie respiratoire : radioprotection grâce à des modèles biologiques étendus et à … Hor09/08/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Outils d’évaluation des risques en cas d’effets secondaires graves après une thérapie respiratoire : radioprotection grâce à des modèles biologiques étendus et à des jumeaux numériques
Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematically mitigated through optimisation and individualisation. Breast cancer (Bca) is the most common cancer in women in Europe, leading to millions of BCa survivors in Europe; this group is projected to increase in the next decades. Randomised trials established the role of RT following breast surgery. Careful RT planning and delivery allow targeting the breast while minimising the dose to organs at risk. Yet, some doses unavoidably reach the lung and the heart, putting BCa patients at risk for severe cardiac and pulmonary disease and second cancers. Quantitative personalised risk scores for late severe cardiac/pulmonary disease/second cancers following RT would reveal opportunities to further mitigate the risk of side effects at the individual patient level. Risk scores would provide a quantitative guide when shaping the patients’ follow-up and screening program to assess the risk or presence of subclinical diseases. Within TETRIS, we propose to design and test quantitative personalised low-level risk scores based on dose-response relationships already published in the literature and refined risk scores which merge patient-specific features (from imaging, genetics and transcriptomics) with RT dose. The project also proposes to explore the opportunities and challenges of applying digital twins (DTs) in RT safety. We will use the historical cohort to develop the prototypes and evaluate the gain we can have using digital twins for risk assessment instead of model-based risk scores. Using a prospective collection of detailed patient data, we will demonstrate the possibility of refining DTs, allowing a deeper description of the single patient and a broader description of the patient’s follow-up. The value of the refined DTs could shape investments in data collection and computational resources for radioprotection.
| Aquilab BY Coexya | 378 875 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 705 000 € |
| Fundacion Publica Galega de Medicina Xenomica | 400 000 € |
| Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio) | 400 000 € |
| Neolys Diagnostics | 350 000 € |
| Politecnico Di Milano | 380 000 € |
| Region Stockholm | 496 844 € |
| Universita Vita-Salute SAN Raffaele | 382 500 € |
https://cordis.europa.eu/project/id/101166699
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.